![conference banner](/images/conference-banner.jpeg)
Abstract
This study established a highly effective and reliable method for the separation and quantitative determination of five pharmacodynamic active components of I. sonchifolia using microemulsion electrokinetic chromatography (MEEKC). The MEEKC conditions were investigated. The optimal running buffer (pH 9.25) consisted of 80 mmol/L Brij-35, 0.8% (v/v) n-heptane, 8% (v/v) 1- butanol, 25% (v/v) acetonitrile, 10 mmol/L sodium dihydrogen phosphate–10 mmol/L sodium borate at 25 kV voltage. The regression equations showed good linear relationships, with 0.61–7.76 µg/mL limit of detection and 2.04–25.85 µg/mL limit of quantitation. The established method was also accurate, with intra-day and inter-day relative standard deviations less than 4.78% and less than 6.27%, respectively. Recovery values ranged from 98.61% to 104.76%. The proposed method was successfully applied to determine the five compounds in Kudiezi injection samples. A MEEKC method without adding neutral markers was further established for dissociation constant (pKa*) measurement, and reliable pKa* values were obtained.
Keywords: Dissociation constant, Ixeris sonchifolia, microemulsion electrokinetic chromatography, quantitation.
Current Pharmaceutical Analysis
Title:Simultaneous Separation, Quantitation, and Determination of the Dissociation Constant of Five Components of Ixeris sonchifolia by Microemulsion Electrokinetic Chromatography
Volume: 12 Issue: 1
Author(s): Dan Guo, Bin Tang, Si Li, Xia Lin, Jiawei He and Hui Li
Affiliation:
Keywords: Dissociation constant, Ixeris sonchifolia, microemulsion electrokinetic chromatography, quantitation.
Abstract: This study established a highly effective and reliable method for the separation and quantitative determination of five pharmacodynamic active components of I. sonchifolia using microemulsion electrokinetic chromatography (MEEKC). The MEEKC conditions were investigated. The optimal running buffer (pH 9.25) consisted of 80 mmol/L Brij-35, 0.8% (v/v) n-heptane, 8% (v/v) 1- butanol, 25% (v/v) acetonitrile, 10 mmol/L sodium dihydrogen phosphate–10 mmol/L sodium borate at 25 kV voltage. The regression equations showed good linear relationships, with 0.61–7.76 µg/mL limit of detection and 2.04–25.85 µg/mL limit of quantitation. The established method was also accurate, with intra-day and inter-day relative standard deviations less than 4.78% and less than 6.27%, respectively. Recovery values ranged from 98.61% to 104.76%. The proposed method was successfully applied to determine the five compounds in Kudiezi injection samples. A MEEKC method without adding neutral markers was further established for dissociation constant (pKa*) measurement, and reliable pKa* values were obtained.
Export Options
About this article
Cite this article as:
Guo Dan, Tang Bin, Li Si, Lin Xia, He Jiawei and Li Hui, Simultaneous Separation, Quantitation, and Determination of the Dissociation Constant of Five Components of Ixeris sonchifolia by Microemulsion Electrokinetic Chromatography, Current Pharmaceutical Analysis 2016; 12 (1) . https://dx.doi.org/10.2174/1573412911666150610210811
DOI https://dx.doi.org/10.2174/1573412911666150610210811 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardioprotection Acquired Through Exercise: The Role of Ischemic Preconditioning
Current Cardiology Reviews Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology Skeletal Myoblasts for Heart Regeneration and Repair: State of the Art and Perspectives on the Mechanisms for Functional Cardiac Benefits
Current Pharmaceutical Design Exercise-Induced MicroRNA Regulation in the Mice Nervous System is Maintained After Activity Cessation
MicroRNA Cardiac Sarcolemmal Ion Channels and Transporters as Possible Targets for Antiarrhythmic and Positive Inotropic Drugs: Strategies of the Past-Perspectives of the Future
Current Pharmaceutical Design MCC950 Reduces Neuronal Apoptosis in Spinal Cord Injury in Mice
CNS & Neurological Disorders - Drug Targets Cellular and Molecular Mechanisms of Curcumin in Thyroid Gland Disorders
Current Medicinal Chemistry Anti-inflammatory Property of AMP-activated Protein Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications
Current Vascular Pharmacology Controlled Release of Growth Factors for Regenerative Medicine
Current Pharmaceutical Design Editorial [Hot Topic: Nitric Oxide (Guest Editor: Greg Thatcher)]
Current Topics in Medicinal Chemistry The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future
Current Pharmaceutical Design Cardiac Dysfunction in Rats with Dietary-Induced Insulin Resistance Associated with Pharmacologically-induced Dyslipidemia
Current Pharmaceutical Design p38 Mitogen-Activated Protein Kinase: A Critical Node Linking Insulin Resistance and Cardiovascular Diseases in Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Gene Therapy in Liver Ischemia and Reperfusion Injury
Current Pharmaceutical Design Exosomal MicroRNA: Diagnostic Marker and Therapeutic Tool for Lung Diseases
Current Pharmaceutical Design Protease Inhibitors in the Clinic
Medicinal Chemistry